ArticleArchives of medical science : AMS2026
High expression of hexokinase 2 promotes lung cancer proliferation and metastasis.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myeloid Cell Leukemia 1 and Hexokinase 2 Directly Interact to Form a Glucose Metabolic Regulatory Axis.Cells · 2026Article
- Autophagy and Glycometabolic Reprograming in the Malignant Progression of Lung Cancer: A Review.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: High metabolic plasticity, as one of the hallmarks of multiple cancers, usually promotes cancer growth and metastasis. Therefore, metabolic enzymes could be selective targets in suppressing the growth and invasion of cancer cells. It is generally believed that hexokinase 2 (HK2) catalysing glucose into glucose-6-phosphate is the first step in glucose metabolism. It is unclear, however, if HK2 is involved in lung cancer (LC) proliferation and metastasis. Material and methods: Tumours and adjacent tissue from LC patients were used to study the expression of HK2 by RT-PCR and western blot analysis. Several different LC cell lines were used to explore the oncogene function of HK2 via MTS and BrdU assay Results: HK2 was upregulated in primary LC tissue and metastatic foci. The expression of HK2 can be modulated by multiple mutations of oncogenes or tumour suppressors, including Kras, p53, and Keap1. Functionally, suppression of HK2 expression by shRNA transfection in LC cell lines hindered lactate production and therefore suppressed cell migration and invasion. The depletion of HK2 also sensitised the LC cells to cisplatin-induced apoptosis, suggesting that HK2 also mediated the chemoresistance in LC. Finally, our Conclusions: We demonstrated that HK2 is required for LC cell growth and metastasis
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.